Trial Profile
An Open-label, Multi-centre, Phase Ib Trial to Determine the Dose of Intravenous BI 836826 in Combination With Oral Venetoclax in Chronic Lymphocytic Leukaemia Patients Who Are Eligible for Treatment With Venetoclax
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BI 836826 (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 08 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Nov 2017 Planned initiation date changed from 1 Dec 2017 to 17 Jan 2018.
- 21 Nov 2017 New trial record